Brand check
Is Pantop banned in India?
Last checked 19 September 2026
Pantop is not banned in India as of 19 Sep 2026; pantoprazole is an essential medicine, and the Pantop-D batch in the CDSCO's December 2025 alert was a spurious sample, not a regulatory action against the brand.
- Classification
- No ban or recall found in official records
- Decided by
- CDSCO / Ministry of Health and Family Welfare
- Reference
- No Section 26A notification; CDSCO monthly drug alert, Dec 2025 (published 21 Jan 2026)
- Latest action
- 21 January 2026
- Last checked
- 19 September 2026
Pantoprazole 20 mg tablets (NIH drug image). Photo: Pantoprazole 20mg.jpg by NLM (Public domain). Brand names and logos belong to their owners and are used here to identify the product this entry is about. All photo credits.
CDSCO: Drug alerts (monthly NSQ / spurious lists)
Scope. A record here does not by itself mean a product or company is unsafe or banned today. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Below: Blacklisted's explanationWe organise and explain what the document says. The document above is the authority.
Key facts
- Governing authority
- CDSCO, Ministry of Health and Family Welfare
- Ban notification
- None
- Dec 2025 alert
- Pantop-D among 7 spurious samples (167 NSQ); published 21 Jan 2026
- Manufacturer
- Aristo Pharmaceuticals
- Halted combinations
- Pantoprazole + domperidone + levosulpiride / + simethicone, 11 Apr 2025 (three-drug products)
Where the claim comes from
The CDSCO's December 2025 alert, published in January 2026, named seven spurious samples including Pantop-D, three Telma-AM batches and two Chymoral Forte batches. Coverage listed the brands, and 'Pantop banned' followed. Generic pantoprazole also appears regularly among NSQ items, which adds to the impression.
Pantop is Aristo's pantoprazole brand, sold plain and as Pantop-D with domperidone. Neither is banned in India.
Pantoprazole is a proton-pump inhibitor on the National List of Essential Medicines and has never been the subject of a Section 26A notification. The two-drug pantoprazole + domperidone combination is likewise not banned; what the CDSCO halted on 11 April 2025 were three-drug versions adding levosulpiride or simethicone, licensed at state level without central approval.
The brand entered the news through the monthly quality alerts. The alert for December 2025, published on 21 January 2026, listed 167 samples not of standard quality and 7 spurious. Among the spurious samples was a Pantop-D batch, alongside three batches of Telma-AM, one of Telma 40, one of Montina-L and two of Chymoral Forte. "Spurious" in these alerts means the sample was not what its label claimed, typically a counterfeit carrying a real brand's name, and manufacturers routinely state that they did not make the batch. Generic pantoprazole tablets from various makers also appear among NSQ items in most months, because the drug is made in such volume.
None of this changes the status of Pantop. A patient with the product should compare the batch number on the strip with the one listed in the December 2025 alert; if it differs, the finding does not concern it. Buying from a licensed pharmacy with a bill is the best protection against counterfeits.
What this means for you
Pantop and Pantop-D remain licensed
The products are on sale; pantoprazole is an essential medicine.
Read the two statements side by side
CDSCO's finding is batch-specific. The company says the batch was not made by it, i.e. counterfeit. Both can be true: someone else made a fake pack with the brand's name.
Compare the batch number
The December 2025 finding concerns one batch; the alert lists it.
This is a record of official orders, not medical advice. Do not stop a prescribed medicine without asking your doctor or pharmacist.
Batches flagged in CDSCO alerts
Products whose name matches this brand or molecule in CDSCO monthly NSQ alerts. A flagged batch is a single batch; the company's response, where reported, is noted on the page above.
| Product | Batch | Manufacturer | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|---|
| Pantoprazole and Domperidone Tablets | T-241215Mfg 2024-12 · Exp 2026-11 | Medirose Drugs And Pharmaceuticals | The sample does not conform to claim with respect to above tests and The sample is not of standard quality for the reason stated under Description.Description | CDL, KolkataCDSCO lab | Jul 2026 |
| Pantoprazole and Domperidone Tablets | AN-06-25Mfg 2025-10 · Exp 2027-09 | Anchor Pharma Pvt. LtdDaman & Diu | TEST FOR DISINTEGRATION TIMEDisintegration | DTL, DelhiState lab | Jul 2026 |
| Pantoprazole Tablets IP | PEP5001Mfg 2025-02 · Exp 2027-01 | Finecure Pharmaceuticals Ltd. PF-5 & 6Gujarat | Dissolution testDissolution | SDT&RL, BhubaneswarState lab | Jul 2026 |
| Pantoprazole Tablets IP | AGW01AKAMfg 2025-09 · Exp 2027-08 | Pure & Cure Healthcare Pvt. LtdUttarakhand | The sample does not conform to IP standards. It fails the test Dissolution.Dissolution | DTL, KonniState lab | Jul 2026 |
| Pantoprazole Gastro-resistant Tablets IP 40 mg | SPK251470Mfg 2025-10 · Exp 2028-03 | Aristo Pharmaceuticals Pvt. Ltd. Plot Nos.: 2040-46Sikkim | Identification - Doesn't conforms to I.P.Identification | Lucknow LabState lab | Jul 2026 |
| Pantoprazole Gastro-resistant Tablets IP 40 mg | 25444650Mfg 2025-12 · Exp 2028-05 | Alkem Health ScienceSikkim | Identification - Doesn't conforms to I.P.Identification | Lucknow LabState lab | Jul 2026 |
| Pantoprazole Gastro-resistant Tablets IP | AT-1952AMfg 2025-06 · Exp 2027-05 | Azot Life SciencesHimachal Pradesh | Content of Pantoprazole (84.7%)Other | Drugs Testing Laboratory, Madurai-19State lab | Jul 2026 |
| Pantoprazole Gastro-resistant and Domperidone Prolonged- released Capsules IP | 25441645Mfg 2025-05 · Exp 2027-04 | Alkem Health ScienceSikkim | TESTS FOR ASSAY (CONTENT) OF PANTOPRAZOLE & UNIFORMITY OF WEIGHTAssay | DTL, DelhiState lab | Jul 2026 |
| Pantoprazole Gastro-resistant Tablets IP | GD25214Mfg 2025-12 · Exp 2027-11 | Skymap Pharmaceuticals Pvt. LtdUttarakhand | TEST FOR DISSOLUTIONDissolution | DTL, DelhiState lab | Jul 2026 |
| Pantoprazole Gastro-Resistant Tablets IP | R2516403JMfg 2025-10 · Exp 2027-09 | Reltsen Healthcare Spl Plot No. 9-11Puducherry | Sample Does not meets the Specifications wrt, Dissolution (All 6 Tablets dissolved in acid stage) as per IPDissolution | DCL, TelanganaState lab | Jul 2026 |
| Pantoprazole Gastro- Resistant & Domperidone Prologed Release Capsules I.P. | CG26-0049RMfg 2026-03 · Exp 2028-02 | Athens Life Sciences Mauza Rampur JattanHimachal Pradesh | 01. ASSAY OF PANTOPRAZOLE SODIUM I.P. & DOMPERIDONE I.P. ? Less than prescribed limit.Assay | SFDTL UttarakhandState lab | Jul 2026 |
| Pantopr azole Gastro Resistant Tablets IP20 mg | CIT-8736Mfg 2025-12 · Exp 2027-11 | Conscaff IndiaHimachal Pradesh | Dissolution TestDissolution | SDTL,Andhra Pradesh, VijayawadaState lab | Jul 2026 |
| Pantoprazole Gastro-resistant Tablets IP | TG25-03290Mfg 2025-02 · Exp 2027-01 | Athens Life SciencesHimachal Pradesh | The sample does not comply as per I.P. 2022 with respect to the test for Dissolution in Acid Stage for Pantoprazole and Description.Dissolution | RDTL, GuwahatiCDSCO lab | Jun 2026 |
| Pantoprazole Gastro-Resistant Tablets IP 40 mg | MMPT9348Mfg 2026-01 · Exp 2027-12 | Middle Mist Pharmaceuticals PvtTamil Nadu | ContentOther | DTL, Madurai-19State lab | Jun 2026 |
| Pantoprazole Gastro Resistant Tablets IP 40 mg | ZTC-165Mfg 2025-03 · Exp 2027-02 | Zoic biotech Pvt . LtdPunjab | The sample does not conform to the IP standards with respect to the test for DissolutionDissolution | DTL, ThrissurState lab | Jun 2026 |
| Pantoprazole Gastro Resistant Tablets IP 40mg | T-3423Mfg 2024-11 · Exp 2026-10 | Jackson Laboratories Pvt. LtdPunjab | Does not conform to IP Standards with respect to Description and Dissolution TestDissolution | FDL, Bambolim GoaState lab | Jun 2026 |
| Pantoprazole Gastro Resistant Tablets IP 40mg | SPG240936Mfg 2024-07 · Exp 2026-12 | Aristo Pharmaceuticals Pvt. LtdSikkim | The sample does not conform to I.P. w.r.to the tests for Identification AssayAssay | SDTL, GuwahatiState lab | Jun 2026 |
| Pantoprazole sodium (EC) & Domperidone (SR) Capsules | MT-25025Mfg 2025-03 · Exp 2027-02 | Shri sai Pharmatech Pvt. Ltd.20Himachal Pradesh | Assay of Domperidone IP- less than prescribed limit.Assay | SDTL, UttarakhandState lab | May 2026 |
| Pantoprazole & Domperidone Tablet | BCV4001DZMfg 2024-07 · Exp 2026-06 | VPAM Healthcare Pvt. Ltd. Plot No. 16&17Himachal Pradesh | Test for Disintegration OnlyDisintegration | RDTL, Bellary, KarnatakaState lab | May 2026 |
| Pantoprazole Sodium Tablets 40 mg | T24.240Mfg 2024-05 · Exp 2026-04 | Oaksun LifesciencesTelangana | Dissolution (buffer stage)Dissolution | SDT&RL, BhubaneswarState lab | Apr 2026 |
Official sources and primary records
- Business Standard: CDSCO flags 7 drugs as spurious, 167 fail quality tests in Dec 2025NewsBusiness Standard · 21 January 2026
- Business Today: India halts 35 drug combinations over health risks, full listNewsBusiness Today · 17 April 2025
- Regulator